New approaches to chronic hepatitis B
G Dusheiko, K Agarwal, MK Maini - New England Journal of …, 2023 - Mass Medical Soc
New Approaches to Chronic Hepatitis B | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Immunological factors linked to geographical variation in vaccine responses
MMAR van Dorst, JJ Pyuza, G Nkurunungi… - Nature Reviews …, 2024 - nature.com
Vaccination is one of medicine's greatest achievements; however, its full potential is
hampered by considerable variation in efficacy across populations and geographical …
hampered by considerable variation in efficacy across populations and geographical …
Relevance of HBx for hepatitis B virus-associated pathogenesis
A Schollmeier, M Glitscher, E Hildt - International Journal of Molecular …, 2023 - mdpi.com
The hepatitis B virus (HBV) counts as a major global health problem, as it presents a
significant causative factor for liver-related morbidity and mortality. The development of …
significant causative factor for liver-related morbidity and mortality. The development of …
Role of CD8+ T cell exhaustion in the progression and prognosis of acute respiratory distress syndrome induced by sepsis: a prospective observational study
L Yan, Y Chen, Y Han, C Tong - BMC Emergency Medicine, 2022 - Springer
Background CD8+ T cells are important for protective immunity against intracellular
pathogens. Excessive amounts of antigen and/or inflammatory signals often lead to the …
pathogens. Excessive amounts of antigen and/or inflammatory signals often lead to the …
What Is the Current Status of Hepatitis B Virus Viro-Immunology?
C Boni, M Rossi, I Montali, C Tiezzi… - Clinics in Liver …, 2023 - liver.theclinics.com
Chronic hepatitis B (CHB) is a major global public problem because at least 262 million
people are chronically infected with hepatitis B virus (HBV). 1 There is therefore an …
people are chronically infected with hepatitis B virus (HBV). 1 There is therefore an …
Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of …
M Al Mahtab, SMF Akbar, JC Aguilar, O Yoshida… - Frontiers in …, 2023 - frontiersin.org
Introduction There is a pressing need to develop novel drugs for treating patients with
chronic hepatitis B (CHB), as commercially available antiviral drugs are endowed with safety …
chronic hepatitis B (CHB), as commercially available antiviral drugs are endowed with safety …
Overview of new targets for hepatitis B virus: immune modulators, interferons, bifunctional peptides, therapeutic vaccines and beyond
J Lok, MFG Veloz, K Agarwal - Clinics in Liver Disease, 2023 - liver.theclinics.com
Hepatitis B virus (HBV) is a global health problem with 262 million people affected
worldwide. Chronic infection may be established within the liver, especially if exposure …
worldwide. Chronic infection may be established within the liver, especially if exposure …
Machine learning combined with single-cell analysis reveals predictive capacity and immunotherapy response of T cell exhaustion-associated lncRNAs in uterine …
F Jiang, Z Tao, Y Zhang, X Xie, Y Bao, Y Hu, J Ding… - Cellular …, 2024 - Elsevier
Background The exhaustion of T-cells is a primary factor contributing to immune dysfunction
in cancer. Long non-coding RNAs (lncRNAs) play a significant role in the advancement …
in cancer. Long non-coding RNAs (lncRNAs) play a significant role in the advancement …
Characteristics of CD8+ Stem Cell-Like Memory T Cell Subset in Chronic Hepatitis C Virus Infection
X Lu, B Song, W Weng, B Su, H Wu, AKL Cheung… - Viral …, 2023 - liebertpub.com
The dysfunction of memory CD8+ T cell cannot be reverted by successful clearance of
hepatitis C virus (HCV) after direct-acting antivirals (DAAs) therapy, increasing the risk of …
hepatitis C virus (HCV) after direct-acting antivirals (DAAs) therapy, increasing the risk of …
Modulation of CD8+ T cells, NK cells and Th1cytokines by metabolic milieu in decline of HBV-viremia in pregnant women treated with tenofovir-disoproxil from second …
High HBV DNA levels predispose to mother to child transmission (MTCT) of HBV. Early
nucleotide analogue (NA) therapy can reduce HBV DNA and minimize MTCT. We analysed …
nucleotide analogue (NA) therapy can reduce HBV DNA and minimize MTCT. We analysed …